Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

por Martinez-Marti, A, Felip, E, Matito, J, Mereu, E, Navarro, A, Cedrés, S, Pardo, N, Martinez de Castro, A, Remon, J, Miquel, J M, Guillaumet-Adkins, A, Nadal, E, Rodriguez-Esteban, G, Arqués, O, Fasani, R, Nuciforo, P, Heyn, H, Villanueva, A, Palmer, H G, Vivancos, A
Publicado 2017